Sodium Chloride Intravenous Infusion 0.9% W/V 100ml

Name: Sodium Chloride Intravenous Infusion 0.9% W/V 100ml
Brand: JIANGXI XIERKANGTAI PHARMACEUTICAL CO., LTD.
SKU: 1965960975

Jiangxi, ChinaJIANGXI XIERKANGTAI PHARMACEUTICAL CO., LTD.

US$0.16

100,000 bottle

Sample price:US$0.01/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Liquid Injection

Model NO.

0.9% W/V 100ml

Suitable for

Adult

State

Liquid

Shape

Liquid Injection

Type

Biological Products

Pharmaceutical Technology

Chemical Synthesis

Price

Low Price

Market

Africa

Transport Package

Carton

Specification

0.9% 100ml

Trademark

OEM

Origin

China

HS Code

3004909099

Production Capacity

100000000PCS

Company profile

Years of Export ExperienceExhibition ExperienceStandardized quality controlFast Delivery

JIANGXI XIERKANGTAI PHARMACEUTICAL CO., LTD.

Jiangxi, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: OEM Service Available CertifiedCustomization Options: Customization from Samples, Customization from Designs CertifiedExport Year: 21 Years CertifiedNearest Port: Shanghai Port, Guangzhou Port, Ningbo PortAverage Response Time: ≤24h

AI-Powered supplier vetting

SummaryJIANGXI XIERKANGTAI PHARMACEUTICAL CO., LTD. is a China-based manufacturing factory established in 2004, with 126 employees and a combined business entity structure. Its stated scope covers pharmaceutical dosage forms, raw-material production and processing, and exports. The supplier reports customization from samples and designs, documented finished-product inspection, complaint handling, traceability, and quality-assurance procedures. It offers OEM services to well-known brands and has six R&D engineers, but reports no new products during the past year, no ODM service, and no SDK. Export sales account for 90% of total sales, with one-month stated lead times in both peak and off-season periods. Certification details are listed only as “Others,” and no cooperation with Fortune 500 companies is reported. Financial credibility cannot be assessed because the provided information does not include non-financial financial evidence.

Supplier typeThe supplier is identified as a factory and limited company in China, established on January 16, 2004, with 126 employees. Its stated business scope includes pharmaceutical production, processing, and export of raw materials, indicating a manufacturing-oriented supplier rather than a purely trading entity.

After-Sales capabilityThe supplier reports documented and followed procedures for handling customer complaints, service-capability assessment, corrective and preventive actions, and supplier management. However, the stated overseas-service coverage is 0 countries, so the evidence supports internal service processes but not broad overseas after-sales reach.

R&D capabilityThe supplier has six R&D engineers and provides OEM services to well-known brands. However, it reports no new products in the past year, no ODM service, and no available SDK, indicating that documented innovation and independent product-development capability are limited.

Production capacityThe supplier lists multiple pharmaceutical and equipment-related production capabilities, has a stated pharmaceutical manufacturing and processing scope, and reports uniformly followed finished-product inspection instructions. It also reports one-month average lead times in both peak and off-season periods, supporting evidence of established production operations.

Customization capabilityThe supplier explicitly supports customization from samples and from customer designs, and also reports OEM capability for well-known brands. Although it does not provide ODM services, the evidence directly supports customer-led customization and OEM production.